% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • ving0000 ving0000 Dec 29, 2011 9:29 AM Flag

    Keeping the gem untouched.

    WE all know agressive partners are eagerly awaiting cash draught to feast like bareheaded Condors on our Ganetespib. Pfizer is experiencing great revenues on targeted therapy, and would spit up big dollars to get a piece of Ganetespib. It would be fast money for us investors, but even better why dont we partner the earlier drugs. For chum change we could easily bring Gante to completion, making it the greatest homerun in the history of small pharma. CEO do you hear me ?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • hi hi, better to keep contact with synta directly, hrrmf... to keep record straight.

    • Hailstorm, those results had nothing to do with the GALAXY study, and you know that. The stock also went up after the early breast trial results were announced. I guess you also forgot to mention the following in the breast cancer studies:

      "Ganetespib shows potent in vitro and in vivo activity against multiple types of breast cancer including HER2-positive, ER/PR positive, triple-negative, and inflammatory breast cancer according to results presented at the San Antonio Breast Cancer Symposium (SABCS). Also reported was an objective response in a patient with metastatic triple-negative breast cancer participating in a ganetespib Phase 1 trial".

      "Synta plans to initiate a company-sponsored trial for ganetespib in both HER2-positive and triple-negative breast cancer in early 2012. In addition, Memorial Sloan Kettering Cancer Center plans to initiate a Phase 1/2 trial evaluating ganetespib in combination with paclitaxel and trastuzumab in HER2-positive breast cancer, and ganetespib in combination with paclitaxel in triple-negative breast cancer."

      Have a great weekend everybody, even the bears!!

    • hihihi hi

    • And I suppose you've already forgotten this gem from last month's presentation?

      "Conclusion: the study did not meet the pre-specified criteria for response rate in the first-stage in this heavily pre-treated group of patients."

    • no, 3 shrinking advanced lung tumors out of 4 is far more tangible than fumes, fog or smoke. Its evidence of STRONG effect, strongest there is.

    • It's all about the science, not NFL drafts or conjecture about big pharma due diligence. If I was in biz development for big pharma, I would want to see the interim GALAXY data before plunking down big upfront money. We will all know if Synta is a 15+ stock or bust by the end of Q2 when the interim results of the GALAXY trial are released. I respect your thoughts, but we are all just blowing smoke until the interim results are announced in the next several months. Since I am not an oncology expert, I had individuals in the oncology field review the science and public clinical data. Although I really like what they told me, I am fully aware of clinical risks in any study. I have witnessed many phase two studies flop in phase three. Some do make it big, and I really like the risk-reward clinical profile of the GALAXY study. Thanks

    • "Scientific rationale?" It's economic. Unless you are in the paranoid fantasy camp that all the big pharma players are out there conspiring to bring down little Synta,view it view it like a football draft. Like NFL teams,all the big pharmas have the money,they are actively competing with each other knowing they need to fill their pipelines, and they have scouted out SNTA and found it lacking. Not ready for the big leagues. I guess it depends on how long you want to hold a $4 stock

    • Sorry, he can't hear you over the roar of my laughter.

    • If the market knew for sure that no partnership was coming the stock would be much lower.

      I suspect that it will stabilize near the current trading price ($4.30) until next week's offering is completed.

    • I've been trying to tell these people that for months now, so I don't expect you'll have any better luck getting them to face reality.

    • View More Messages
0.343+0.072(+26.61%)Jul 22 4:00 PMEDT